The phase 3 FINE-ONE study investigated finerenone in adult patients with type 1 diabetes and chronic kidney disease.[2] The study involved 242 participants who received 10 or 20 mg of finerenone daily for six months along with standard treatment.[2] The primary endpoint was met: finerenone reduced urinary albumin to creatinine ratio (UACR) by 25% versus placebo (95% CI = 0.75 [0.65–0.87]; p=0.0001).[2] UACR is a biomarker of kidney disease progression and cardiovascular risk.[2] Adverse events occurred in 47.1% of patients on finerenone and 49.2% on placebo, serious adverse events in 11.8% and 11.5%, respectively.[2] Hyperkalemia was reported in 10.1% of patients on finerenone versus 3.3% on placebo, discontinuation due to it in 1.7% and 0%, respectively.[2] The safety results are consistent with previous studies of finerenone in type 2 diabetes.[2] Bayer plans to submit a supplemental application based on these results in 2026.[2]